Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,085
archived clinical trials in
Cervical Cancer

To Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
An Open-Label Randomized, Phase 2A, Dose-ranging Study of Sotatercept (ACE-011) for Chemotherapy-Induced Anemia in Subjects With Advanced or Metastatic Solid Tumors Treated With Platinum-Based Chemotherapeutic Regimens
Status: Enrolling
Updated:  11/14/2017
Comprehensive Cancer Centers of Nevada (TORI)
mi
from
Henderson, NV
To Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
An Open-Label Randomized, Phase 2A, Dose-ranging Study of Sotatercept (ACE-011) for Chemotherapy-Induced Anemia in Subjects With Advanced or Metastatic Solid Tumors Treated With Platinum-Based Chemotherapeutic Regimens
Status: Enrolling
Updated: 11/14/2017
Comprehensive Cancer Centers of Nevada (TORI)
mi
from
Henderson, NV
Click here to add this to my saved trials
To Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
An Open-Label Randomized, Phase 2A, Dose-ranging Study of Sotatercept (ACE-011) for Chemotherapy-Induced Anemia in Subjects With Advanced or Metastatic Solid Tumors Treated With Platinum-Based Chemotherapeutic Regimens
Status: Enrolling
Updated:  11/14/2017
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
To Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
An Open-Label Randomized, Phase 2A, Dose-ranging Study of Sotatercept (ACE-011) for Chemotherapy-Induced Anemia in Subjects With Advanced or Metastatic Solid Tumors Treated With Platinum-Based Chemotherapeutic Regimens
Status: Enrolling
Updated: 11/14/2017
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
To Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
An Open-Label Randomized, Phase 2A, Dose-ranging Study of Sotatercept (ACE-011) for Chemotherapy-Induced Anemia in Subjects With Advanced or Metastatic Solid Tumors Treated With Platinum-Based Chemotherapeutic Regimens
Status: Enrolling
Updated:  11/14/2017
Monter Cancer Center, North Shore LIJ Health Systems
mi
from
Lake Success, NY
To Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
An Open-Label Randomized, Phase 2A, Dose-ranging Study of Sotatercept (ACE-011) for Chemotherapy-Induced Anemia in Subjects With Advanced or Metastatic Solid Tumors Treated With Platinum-Based Chemotherapeutic Regimens
Status: Enrolling
Updated: 11/14/2017
Monter Cancer Center, North Shore LIJ Health Systems
mi
from
Lake Success, NY
Click here to add this to my saved trials
To Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
An Open-Label Randomized, Phase 2A, Dose-ranging Study of Sotatercept (ACE-011) for Chemotherapy-Induced Anemia in Subjects With Advanced or Metastatic Solid Tumors Treated With Platinum-Based Chemotherapeutic Regimens
Status: Enrolling
Updated:  11/14/2017
Duke Univ Med Ctr
mi
from
Durham, NC
To Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
An Open-Label Randomized, Phase 2A, Dose-ranging Study of Sotatercept (ACE-011) for Chemotherapy-Induced Anemia in Subjects With Advanced or Metastatic Solid Tumors Treated With Platinum-Based Chemotherapeutic Regimens
Status: Enrolling
Updated: 11/14/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
To Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
An Open-Label Randomized, Phase 2A, Dose-ranging Study of Sotatercept (ACE-011) for Chemotherapy-Induced Anemia in Subjects With Advanced or Metastatic Solid Tumors Treated With Platinum-Based Chemotherapeutic Regimens
Status: Enrolling
Updated:  11/14/2017
Piedmont Hematology-Oncology Associates
mi
from
Winston-Salem, NC
To Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
An Open-Label Randomized, Phase 2A, Dose-ranging Study of Sotatercept (ACE-011) for Chemotherapy-Induced Anemia in Subjects With Advanced or Metastatic Solid Tumors Treated With Platinum-Based Chemotherapeutic Regimens
Status: Enrolling
Updated: 11/14/2017
Piedmont Hematology-Oncology Associates
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
To Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
An Open-Label Randomized, Phase 2A, Dose-ranging Study of Sotatercept (ACE-011) for Chemotherapy-Induced Anemia in Subjects With Advanced or Metastatic Solid Tumors Treated With Platinum-Based Chemotherapeutic Regimens
Status: Enrolling
Updated:  11/14/2017
Gabrail Cancer Center
mi
from
Canton, OH
To Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
An Open-Label Randomized, Phase 2A, Dose-ranging Study of Sotatercept (ACE-011) for Chemotherapy-Induced Anemia in Subjects With Advanced or Metastatic Solid Tumors Treated With Platinum-Based Chemotherapeutic Regimens
Status: Enrolling
Updated: 11/14/2017
Gabrail Cancer Center
mi
from
Canton, OH
Click here to add this to my saved trials
To Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
An Open-Label Randomized, Phase 2A, Dose-ranging Study of Sotatercept (ACE-011) for Chemotherapy-Induced Anemia in Subjects With Advanced or Metastatic Solid Tumors Treated With Platinum-Based Chemotherapeutic Regimens
Status: Enrolling
Updated:  11/14/2017
Saint Charles Medical Center
mi
from
Bend, OR
To Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
An Open-Label Randomized, Phase 2A, Dose-ranging Study of Sotatercept (ACE-011) for Chemotherapy-Induced Anemia in Subjects With Advanced or Metastatic Solid Tumors Treated With Platinum-Based Chemotherapeutic Regimens
Status: Enrolling
Updated: 11/14/2017
Saint Charles Medical Center
mi
from
Bend, OR
Click here to add this to my saved trials
To Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
An Open-Label Randomized, Phase 2A, Dose-ranging Study of Sotatercept (ACE-011) for Chemotherapy-Induced Anemia in Subjects With Advanced or Metastatic Solid Tumors Treated With Platinum-Based Chemotherapeutic Regimens
Status: Enrolling
Updated:  11/14/2017
Willamette Valley Cancer Institute/Research Ctr
mi
from
Eugene, OR
To Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
An Open-Label Randomized, Phase 2A, Dose-ranging Study of Sotatercept (ACE-011) for Chemotherapy-Induced Anemia in Subjects With Advanced or Metastatic Solid Tumors Treated With Platinum-Based Chemotherapeutic Regimens
Status: Enrolling
Updated: 11/14/2017
Willamette Valley Cancer Institute/Research Ctr
mi
from
Eugene, OR
Click here to add this to my saved trials
To Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
An Open-Label Randomized, Phase 2A, Dose-ranging Study of Sotatercept (ACE-011) for Chemotherapy-Induced Anemia in Subjects With Advanced or Metastatic Solid Tumors Treated With Platinum-Based Chemotherapeutic Regimens
Status: Enrolling
Updated:  11/14/2017
The West Clinic, PC
mi
from
Memphis, TN
To Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
An Open-Label Randomized, Phase 2A, Dose-ranging Study of Sotatercept (ACE-011) for Chemotherapy-Induced Anemia in Subjects With Advanced or Metastatic Solid Tumors Treated With Platinum-Based Chemotherapeutic Regimens
Status: Enrolling
Updated: 11/14/2017
The West Clinic, PC
mi
from
Memphis, TN
Click here to add this to my saved trials
To Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
An Open-Label Randomized, Phase 2A, Dose-ranging Study of Sotatercept (ACE-011) for Chemotherapy-Induced Anemia in Subjects With Advanced or Metastatic Solid Tumors Treated With Platinum-Based Chemotherapeutic Regimens
Status: Enrolling
Updated:  11/14/2017
Vanderbilt University Medical Center
mi
from
Nashville, TN
To Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
An Open-Label Randomized, Phase 2A, Dose-ranging Study of Sotatercept (ACE-011) for Chemotherapy-Induced Anemia in Subjects With Advanced or Metastatic Solid Tumors Treated With Platinum-Based Chemotherapeutic Regimens
Status: Enrolling
Updated: 11/14/2017
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
To Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
An Open-Label Randomized, Phase 2A, Dose-ranging Study of Sotatercept (ACE-011) for Chemotherapy-Induced Anemia in Subjects With Advanced or Metastatic Solid Tumors Treated With Platinum-Based Chemotherapeutic Regimens
Status: Enrolling
Updated:  11/14/2017
Texas Oncology, P.A. - Bedford
mi
from
Bedford, TX
To Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
An Open-Label Randomized, Phase 2A, Dose-ranging Study of Sotatercept (ACE-011) for Chemotherapy-Induced Anemia in Subjects With Advanced or Metastatic Solid Tumors Treated With Platinum-Based Chemotherapeutic Regimens
Status: Enrolling
Updated: 11/14/2017
Texas Oncology, P.A. - Bedford
mi
from
Bedford, TX
Click here to add this to my saved trials
To Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
An Open-Label Randomized, Phase 2A, Dose-ranging Study of Sotatercept (ACE-011) for Chemotherapy-Induced Anemia in Subjects With Advanced or Metastatic Solid Tumors Treated With Platinum-Based Chemotherapeutic Regimens
Status: Enrolling
Updated:  11/14/2017
Mary Crowley Medical Research Center
mi
from
Dallas, TX
To Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
An Open-Label Randomized, Phase 2A, Dose-ranging Study of Sotatercept (ACE-011) for Chemotherapy-Induced Anemia in Subjects With Advanced or Metastatic Solid Tumors Treated With Platinum-Based Chemotherapeutic Regimens
Status: Enrolling
Updated: 11/14/2017
Mary Crowley Medical Research Center
mi
from
Dallas, TX
Click here to add this to my saved trials
To Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
An Open-Label Randomized, Phase 2A, Dose-ranging Study of Sotatercept (ACE-011) for Chemotherapy-Induced Anemia in Subjects With Advanced or Metastatic Solid Tumors Treated With Platinum-Based Chemotherapeutic Regimens
Status: Enrolling
Updated:  11/14/2017
University of Texas Medical Branch
mi
from
Galveston, TX
To Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
An Open-Label Randomized, Phase 2A, Dose-ranging Study of Sotatercept (ACE-011) for Chemotherapy-Induced Anemia in Subjects With Advanced or Metastatic Solid Tumors Treated With Platinum-Based Chemotherapeutic Regimens
Status: Enrolling
Updated: 11/14/2017
University of Texas Medical Branch
mi
from
Galveston, TX
Click here to add this to my saved trials
To Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
An Open-Label Randomized, Phase 2A, Dose-ranging Study of Sotatercept (ACE-011) for Chemotherapy-Induced Anemia in Subjects With Advanced or Metastatic Solid Tumors Treated With Platinum-Based Chemotherapeutic Regimens
Status: Enrolling
Updated:  11/14/2017
Allison Cancer Center
mi
from
Midland, TX
To Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
An Open-Label Randomized, Phase 2A, Dose-ranging Study of Sotatercept (ACE-011) for Chemotherapy-Induced Anemia in Subjects With Advanced or Metastatic Solid Tumors Treated With Platinum-Based Chemotherapeutic Regimens
Status: Enrolling
Updated: 11/14/2017
Allison Cancer Center
mi
from
Midland, TX
Click here to add this to my saved trials
To Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
An Open-Label Randomized, Phase 2A, Dose-ranging Study of Sotatercept (ACE-011) for Chemotherapy-Induced Anemia in Subjects With Advanced or Metastatic Solid Tumors Treated With Platinum-Based Chemotherapeutic Regimens
Status: Enrolling
Updated:  11/14/2017
Northwestern Medical Specialists, PLLC
mi
from
Tacoma, WA
To Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
An Open-Label Randomized, Phase 2A, Dose-ranging Study of Sotatercept (ACE-011) for Chemotherapy-Induced Anemia in Subjects With Advanced or Metastatic Solid Tumors Treated With Platinum-Based Chemotherapeutic Regimens
Status: Enrolling
Updated: 11/14/2017
Northwestern Medical Specialists, PLLC
mi
from
Tacoma, WA
Click here to add this to my saved trials
To Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
An Open-Label Randomized, Phase 2A, Dose-ranging Study of Sotatercept (ACE-011) for Chemotherapy-Induced Anemia in Subjects With Advanced or Metastatic Solid Tumors Treated With Platinum-Based Chemotherapeutic Regimens
Status: Enrolling
Updated:  11/14/2017
Henry Ford Health System
mi
from
Detroit, MI
To Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
An Open-Label Randomized, Phase 2A, Dose-ranging Study of Sotatercept (ACE-011) for Chemotherapy-Induced Anemia in Subjects With Advanced or Metastatic Solid Tumors Treated With Platinum-Based Chemotherapeutic Regimens
Status: Enrolling
Updated: 11/14/2017
Henry Ford Health System
mi
from
Detroit, MI
Click here to add this to my saved trials
To Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
An Open-Label Randomized, Phase 2A, Dose-ranging Study of Sotatercept (ACE-011) for Chemotherapy-Induced Anemia in Subjects With Advanced or Metastatic Solid Tumors Treated With Platinum-Based Chemotherapeutic Regimens
Status: Enrolling
Updated:  11/14/2017
University of Cincinnati Physicians, Inc
mi
from
Cincinnati, OH
To Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
An Open-Label Randomized, Phase 2A, Dose-ranging Study of Sotatercept (ACE-011) for Chemotherapy-Induced Anemia in Subjects With Advanced or Metastatic Solid Tumors Treated With Platinum-Based Chemotherapeutic Regimens
Status: Enrolling
Updated: 11/14/2017
University of Cincinnati Physicians, Inc
mi
from
Cincinnati, OH
Click here to add this to my saved trials
To Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
An Open-Label Randomized, Phase 2A, Dose-ranging Study of Sotatercept (ACE-011) for Chemotherapy-Induced Anemia in Subjects With Advanced or Metastatic Solid Tumors Treated With Platinum-Based Chemotherapeutic Regimens
Status: Enrolling
Updated:  11/14/2017
Cancer Centers of the Carolinas
mi
from
Greenville, SC
To Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
An Open-Label Randomized, Phase 2A, Dose-ranging Study of Sotatercept (ACE-011) for Chemotherapy-Induced Anemia in Subjects With Advanced or Metastatic Solid Tumors Treated With Platinum-Based Chemotherapeutic Regimens
Status: Enrolling
Updated: 11/14/2017
Cancer Centers of the Carolinas
mi
from
Greenville, SC
Click here to add this to my saved trials
To Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
An Open-Label Randomized, Phase 2A, Dose-ranging Study of Sotatercept (ACE-011) for Chemotherapy-Induced Anemia in Subjects With Advanced or Metastatic Solid Tumors Treated With Platinum-Based Chemotherapeutic Regimens
Status: Enrolling
Updated:  11/14/2017
Oncology & Hematology Associates Of Southwest Virginia, Inc.
mi
from
Salem, VA
To Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
An Open-Label Randomized, Phase 2A, Dose-ranging Study of Sotatercept (ACE-011) for Chemotherapy-Induced Anemia in Subjects With Advanced or Metastatic Solid Tumors Treated With Platinum-Based Chemotherapeutic Regimens
Status: Enrolling
Updated: 11/14/2017
Oncology & Hematology Associates Of Southwest Virginia, Inc.
mi
from
Salem, VA
Click here to add this to my saved trials
Psychological Interventions for Gynecologic Cancer
Psychological Interventions for Gynecologic Cancer
Status: Enrolling
Updated:  11/15/2017
The Cooper Health System
mi
from
Camden, NJ
Psychological Interventions for Gynecologic Cancer
Psychological Interventions for Gynecologic Cancer
Status: Enrolling
Updated: 11/15/2017
The Cooper Health System
mi
from
Camden, NJ
Click here to add this to my saved trials
Psychological Interventions for Gynecologic Cancer
Psychological Interventions for Gynecologic Cancer
Status: Enrolling
Updated:  11/15/2017
Cancer Institute of New Jersey at Hamilton
mi
from
Hamilton, NJ
Psychological Interventions for Gynecologic Cancer
Psychological Interventions for Gynecologic Cancer
Status: Enrolling
Updated: 11/15/2017
Cancer Institute of New Jersey at Hamilton
mi
from
Hamilton, NJ
Click here to add this to my saved trials
Psychological Interventions for Gynecologic Cancer
Psychological Interventions for Gynecologic Cancer
Status: Enrolling
Updated:  11/15/2017
Morristown Medical Center
mi
from
Morristown, NJ
Psychological Interventions for Gynecologic Cancer
Psychological Interventions for Gynecologic Cancer
Status: Enrolling
Updated: 11/15/2017
Morristown Medical Center
mi
from
Morristown, NJ
Click here to add this to my saved trials
Psychological Interventions for Gynecologic Cancer
Psychological Interventions for Gynecologic Cancer
Status: Enrolling
Updated:  11/15/2017
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Psychological Interventions for Gynecologic Cancer
Psychological Interventions for Gynecologic Cancer
Status: Enrolling
Updated: 11/15/2017
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Psychological Interventions for Gynecologic Cancer
Psychological Interventions for Gynecologic Cancer
Status: Enrolling
Updated:  11/15/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Psychological Interventions for Gynecologic Cancer
Psychological Interventions for Gynecologic Cancer
Status: Enrolling
Updated: 11/15/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Psychological Interventions for Gynecologic Cancer
Psychological Interventions for Gynecologic Cancer
Status: Enrolling
Updated:  11/15/2017
Jefferson University School of Medicine
mi
from
Philadelphia, PA
Psychological Interventions for Gynecologic Cancer
Psychological Interventions for Gynecologic Cancer
Status: Enrolling
Updated: 11/15/2017
Jefferson University School of Medicine
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Psychological Interventions for Gynecologic Cancer
Psychological Interventions for Gynecologic Cancer
Status: Enrolling
Updated:  11/15/2017
Thomas Jefferson University
mi
from
Philadelphia, PA
Psychological Interventions for Gynecologic Cancer
Psychological Interventions for Gynecologic Cancer
Status: Enrolling
Updated: 11/15/2017
Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Psychological Interventions for Gynecologic Cancer
Psychological Interventions for Gynecologic Cancer
Status: Enrolling
Updated:  11/15/2017
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Psychological Interventions for Gynecologic Cancer
Psychological Interventions for Gynecologic Cancer
Status: Enrolling
Updated: 11/15/2017
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Psychological Interventions for Gynecologic Cancer
Psychological Interventions for Gynecologic Cancer
Status: Enrolling
Updated:  11/15/2017
University of Pennsylvania Health System
mi
from
Philadelphia, PA
Psychological Interventions for Gynecologic Cancer
Psychological Interventions for Gynecologic Cancer
Status: Enrolling
Updated: 11/15/2017
University of Pennsylvania Health System
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Zoledronate in Treating Patients With Cervical Intraepithelial Neoplasia 2/3 or 3
An Exploratory Clinical Trial of Zoledronic Acid in Women With CIN 2/3 or 3
Status: Enrolling
Updated:  11/21/2017
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Zoledronate in Treating Patients With Cervical Intraepithelial Neoplasia 2/3 or 3
An Exploratory Clinical Trial of Zoledronic Acid in Women With CIN 2/3 or 3
Status: Enrolling
Updated: 11/21/2017
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Erlotinib, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB-Stage IVA Cervical Cancer
Erlotinib in Combination With Cisplatin as Radiosensitizing Agents in Women Receiving Radiation Therapy for Locally Advanced Squamous Cell Carcinoma of the Cervix; A Phase I Trial
Status: Enrolling
Updated:  11/27/2017
University of Minnesota Cancer Center
mi
from
Minneapolis, MN
Erlotinib, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB-Stage IVA Cervical Cancer
Erlotinib in Combination With Cisplatin as Radiosensitizing Agents in Women Receiving Radiation Therapy for Locally Advanced Squamous Cell Carcinoma of the Cervix; A Phase I Trial
Status: Enrolling
Updated: 11/27/2017
University of Minnesota Cancer Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
DNA Array Analysis of Patients With Cervical Cancer
A Pilot Study of Early Changes in DNA Array Expression Following Chemo-Radiation Treatment of Cervical Cancer
Status: Enrolling
Updated:  11/28/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
DNA Array Analysis of Patients With Cervical Cancer
A Pilot Study of Early Changes in DNA Array Expression Following Chemo-Radiation Treatment of Cervical Cancer
Status: Enrolling
Updated: 11/28/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Cancer and Mindfulness-Based Cancer Recovery After Chemotherapy
Cancer and Mindfulness-Based Cancer Recovery After Chemotherapy
Status: Enrolling
Updated:  11/29/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Cancer and Mindfulness-Based Cancer Recovery After Chemotherapy
Cancer and Mindfulness-Based Cancer Recovery After Chemotherapy
Status: Enrolling
Updated: 11/29/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Topotecan, Cisplatin, and Radiation Therapy in Treating Patients With Advanced Cervical Cancer
A Phase I Study of Adjuvant Topotecan and Cisplatin With Concurrent Radiation Therapy for Advanced Cervical Cancer
Status: Enrolling
Updated:  11/29/2017
University of Minnesota Cancer Center
mi
from
Minneapolis, MN
Topotecan, Cisplatin, and Radiation Therapy in Treating Patients With Advanced Cervical Cancer
A Phase I Study of Adjuvant Topotecan and Cisplatin With Concurrent Radiation Therapy for Advanced Cervical Cancer
Status: Enrolling
Updated: 11/29/2017
University of Minnesota Cancer Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  12/1/2017
The Hartford Hospital
mi
from
Hartford, CT
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 12/1/2017
The Hartford Hospital
mi
from
Hartford, CT
Click here to add this to my saved trials
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  12/1/2017
The Hospital of Central Connecticut
mi
from
New Britain, CT
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 12/1/2017
The Hospital of Central Connecticut
mi
from
New Britain, CT
Click here to add this to my saved trials
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  12/1/2017
Memorial University Medical Center
mi
from
Savannah, GA
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 12/1/2017
Memorial University Medical Center
mi
from
Savannah, GA
Click here to add this to my saved trials
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  12/1/2017
Rush University Medical Center
mi
from
Chicago, IL
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 12/1/2017
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  12/1/2017
University of Chicago
mi
from
Chicago, IL
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 12/1/2017
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  12/1/2017
Sudarshan K Sharma MD Limted-Gynecologic Oncology
mi
from
Hinsdale, IL
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 12/1/2017
Sudarshan K Sharma MD Limted-Gynecologic Oncology
mi
from
Hinsdale, IL
Click here to add this to my saved trials
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  12/1/2017
Elkhart General Hospital
mi
from
Elkhart, IN
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 12/1/2017
Elkhart General Hospital
mi
from
Elkhart, IN
Click here to add this to my saved trials
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  12/1/2017
Indiana University Medical Center
mi
from
Indianapolis, IN
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 12/1/2017
Indiana University Medical Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  12/1/2017
Saint Vincent Hospital and Health Services
mi
from
Indianapolis, IN
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 12/1/2017
Saint Vincent Hospital and Health Services
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  12/1/2017
Community Howard Regional Health
mi
from
Kokomo, IN
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 12/1/2017
Community Howard Regional Health
mi
from
Kokomo, IN
Click here to add this to my saved trials
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  12/1/2017
IU Health La Porte Hospital
mi
from
La Porte, IN
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 12/1/2017
IU Health La Porte Hospital
mi
from
La Porte, IN
Click here to add this to my saved trials
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  12/1/2017
Saint Joseph Regional Medical Center-Mishawaka
mi
from
Mishawaka, IN
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 12/1/2017
Saint Joseph Regional Medical Center-Mishawaka
mi
from
Mishawaka, IN
Click here to add this to my saved trials
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  12/1/2017
Memorial Hospital of South Bend
mi
from
South Bend, IN
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 12/1/2017
Memorial Hospital of South Bend
mi
from
South Bend, IN
Click here to add this to my saved trials
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  12/1/2017
South Bend Clinic
mi
from
South Bend, IN
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 12/1/2017
South Bend Clinic
mi
from
South Bend, IN
Click here to add this to my saved trials
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  12/1/2017
Northern Indiana Cancer Research Consortium
mi
from
South Bend, IN
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 12/1/2017
Northern Indiana Cancer Research Consortium
mi
from
South Bend, IN
Click here to add this to my saved trials
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  12/1/2017
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 12/1/2017
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Click here to add this to my saved trials
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  12/1/2017
Gynecologic Oncology of West Michigan
mi
from
Grand Rapids, MI
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 12/1/2017
Gynecologic Oncology of West Michigan
mi
from
Grand Rapids, MI
Click here to add this to my saved trials